Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment

Tefferi, Ayalew; Dewald, Gordon W.; Litzow, Mark L.; Cortes, Jorge; Mauro, Michael J.; Talpaz, Moshe; Kantarjian, Hagop M.
March 2005
Mayo Clinic Proceedings;Mar2005, Vol. 80 Issue 3, p390
Academic Journal
Chronic myeloid leukemia provides an Illustrative disease model for both molecular pathogenesis of cancer and rational drug therapy. Chronic myeloid leukemia is a clonal stem cell disease caused by an acquired somatic mutation that fuses, through chromosomal translocation, the abl and bcr genes on chromosomes 9 and 22, respectively. The bcr/abl gene product is an oncogenic protein that localizes to the cytoskeleton and displays an up-regulated tyrosine kinase activity that leads to the recruitment of downstream effectors of cell proliferation and cell survival and consequently cell transformation. Such molecular Information on pathogenesis has facilitated accurate diagnosis, the development of pathogenesis-targeted drug therapy, and most recently the application of molecular techniques for monitoring minimal residual disease after successful therapy. These issues are discussed within the context of clinical practice.


Related Articles

  • Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients. Chou, W.-C.; Chen, C.-Y.; Hou, H.-A.; Lin, L.-I.; Tang, J.-L.; Yao, M.; Tsay, W.; Ko, B.-S.; Wu, S.-J.; Huang, S.-Y.; Hsu, S.-C.; Chen, Y.-C.; Huang, Y.-N.; Tseng, M.-H.; Huang, C.-F.; Tien, H.-F. // Leukemia (08876924);Jul2009, Vol. 23 Issue 7, p1303 

    Acute myeloid leukemia (AML) with t(7;11)(p15;p15), which results in a NUP98–HOXA9 fusion, is a distinct entity, but this subtype has not been characterized in detail. In a comprehensive study comparing 11 such patients with another 482 adult patients, we found that those with t(7;11)...

  • Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features. Chauhan, Pradeep S.; Bhushan, Bharat; Mishra, Ashwani K.; Singh, Laishram C.; Saluja, Sumita; Verma, Saurabh; Gupta, Dipendra K.; Mittal, Vishakha; Chaudhry, Sumita; Kapur, Sujala // Medical Oncology;Jun2011, Vol. 28 Issue 2, p544 

    ute myeloid leukemia (AML) with normal karyotype represents a clinically and molecularly heterogeneous disease. Molecular markers with prognostic significance have been examined to improve risk profile characterization of this group. Activating mutations on FLT3 receptor are one of the most...

  • Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms. Chun Hang Au; Anna Wa; Ho, Dona N.; Tsun Leung Chan; Ma, Edmond S. K. // Diagnostic Pathology;1/22/2016, Vol. 11, p1 

    Background: Genomic techniques in recent years have allowed the identification of many mutated genes important in the pathogenesis of acute myeloid leukemia (AML). Together with cytogenetic aberrations, these gene mutations are powerful prognostic markers in AML and can be used to guide patient...

  • AML with t(8;21) and trisomy 4: possible involvement of c-kit? Langabeer, S.E.; Beghini, A.; Larizza, L. // Leukemia (08876924);Sep2003, Vol. 17 Issue 9, p1915 

    Describes the minor subset of acute myeloid leukemia (AML) patients with trisomy who had relatively poor prognosis. Current theory regarding the pathogenesis of AML; Detection of the presence of mutations of the c-kit gne at the chromosomes; Inhibition of kit tyrosine activity.

  • Mutations of the transcription factor AML1/CBA2 are uncommon in blastic transformation of chronic myeloid leukaemia. Steer, E J; Goldman, J M; Cross, N C P // Leukemia (08876924);Mar2001, Vol. 15 Issue 3, p476 

    Reports on occurrence of mutations of a transcription factor in blastic transformation of chronic myeloid leukemia. Techniques used to extract DNA samples from the bone marrow of patients; Description of the mutated gene CBFA2.

  • Gene mutations and molecularly targeted therapies in acute myeloid leukemia. Hatzimichael, Eleftheria; Georgiou, Georgios; Benetatos, Leonidas; Briasoulis, Evangelos // American Journal of Blood Research;2013, Vol. 3 Issue 1, p29 

    Acute myelogenous leukemia (AML) can progress quickly and without treatment can become fatal in a short period of time. However, over the last 30 years fine-tuning of therapeutics have increased the rates of remission and cure. Cytogenetics and mutational gene profiling, combined with the option...

  • Acute Myeloid Leukemia With IDH1 or IDH2 Mutation. Patel, Keyur P.; Ravandi, Farhad; Ma, Deqin; Paladugu, Abhaya; Barkoh, Bedia A.; Medeiros, L. Jeffrey; Luthra, Rajyalakshmi // American Journal of Clinical Pathology;Jan2011, Vol. 135 Issue 1, p35 

    Mutations in the isocitrate dehydrogenase 1 (IDH1) and IDH2 genes are reported in acute myeloid leukemia (AML). We studied the frequency and the clinicopathologic features of IDH1 and IDH2 mutations in AML. Mutations in IDH1 (IDH1R132) and IDH2 (IDH2R172) were assessed by Sanger sequencing in...

  • Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia. Sivagnanalingam, Umayal; Balys, Marlene; Eberhardt, Allison; Wang, Nancy; Myers, Jason R.; Ashton, John M.; Becker, Michael W.; Calvi, Laura M.; Mendler, Jason H. // PLoS ONE;7/15/2015, Vol. 10 Issue 7, p1 

    Cytogenetically normal acute myeloid leukemia (CN-AML) patients harboring RUNX1 mutations have a dismal prognosis with anthracycline/cytarabine-based chemotherapy. We aimed to develop an in vivo model of RUNX1-mutated, CN-AML in which the nature of residual disease in this molecular disease...

  • Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Hou, H-A; Lin, C-C; Chou, W-C; Liu, C-Y; Chen, C-Y; Tang, J-L; Lai, Y-J; Tseng, M-H; Huang, C-F; Chiang, Y-C; Lee, F-Y; Kuo, Y-Y; Lee, M-C; Liu, M-C; Liu, C-W; Lin, L-I; Yao, M; Huang, S-Y; Ko, B-S; Hsu, S-C // Leukemia (08876924);Jan2014, Vol. 28 Issue 1, p50 

    Conventionally, acute myeloid leukemia (AML) patients are categorized into good-, intermediate- and poor-risk groups according to cytogenetic changes. However, patients with intermediate-risk cytogenetics represent a largely heterogeneous population regarding treatment response and clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics